PMID- 36017200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220827
IS  - 2618-6500 (Electronic)
IS  - 2148-5046 (Print)
IS  - 2148-5046 (Linking)
VI  - 37
IP  - 2
DP  - 2022 Jun
TI  - Is COVID-19 multisystem inflammatory syndrome a new variant of Kawasaki Disease?
PG  - 230-244
LID - 10.46497/ArchRheumatol.2022.9086 [doi]
AB  - OBJECTIVES: In this systematic review, we aimed to evaluate the clinical 
      features, therapeutic options, and outcomes of children with multisystem 
      inflammatory syndrome in children (MIS-C) and to investigate whether MIS-C is a 
      new variant of Kawasaki disease. MATERIALS AND METHODS: Adhering to PRISMA 
      principles, we searched for eligible studies between December 2019 and June 2020 
      through the following databases: PubMed, ISI Web of Science, SCOPUS, and Science 
      Direct. Studies including original data of patients aged <21 years with MIS-C and 
      descriptions of clinical signs, laboratory or radiological investigations were 
      selected. RESULTS: A total of 84 studies were identified, for which 48 were 
      eligible for full screening and only 13 studies (n=657) met our inclusion 
      criteria. More than 70% of patients with MIS-C tested positive for severe acute 
      respiratory syndrome-coronavirus 2 (SARS-CoV-2). The most common symptoms were 
      gastrointestinal (80 to 100%) and most patients presented with fever for >4 days. 
      Mucocutaneous manifestations are similar to Kawasaki disease presented in up to 
      64% in some studies. Almost all patients had significant elevations in 
      inflammatory markers, and up to 50 to 100% had elevated troponin suggesting 
      myocardial damage. Intravenous immunoglobulin (IVIG) was administered to 60% of 
      patients in 12 studies and 80 to 100% in five studies. Steroids were administered 
      to 10 to 95% of patients. The overall mortality rate was 0.9%. CONCLUSION: The 
      temporal association between novel coronavirus disease 2019 (COVID-19) onset and 
      Kawasaki-like disease and MIS-C suggests a causal link. Both syndromes have 
      similar cascades of symptoms and hyperinflammation, which likely explain their 
      response to the same immunomodulatory agents. However, it is unclear yet why some 
      children appear more susceptible to develop MIS-C.
CI  - Copyright (c) 2022, Turkish League Against Rheumatism.
FAU - Abu Hammour, Khawla
AU  - Abu Hammour K
AUID- ORCID: 0000-0002-7861-1958
AD  - Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, 
      Amman, Jordan.
FAU - Abu Farha, Rana
AU  - Abu Farha R
AUID- ORCID: 0000-0001-8298-4071
AD  - Department of Clinical Pharmacy and Therapeutics, Applied Science Private 
      University, Amman, Jordan.
FAU - Manaseer, Qusai
AU  - Manaseer Q
AD  - Department of Orthopaedic, The University of Jordan, School of Medicine, Amman, 
      Jordan.
FAU - Dawoud, Tasnim
AU  - Dawoud T
AD  - Tawam Hospital, Al Ain, UAE, 4. Neonatal and Pediatric Critical Care, Al- Ein, 
      United Arab Emirates.
FAU - Abu Hammour, Walid
AU  - Abu Hammour W
AUID- ORCID: 0000-0002-2861-1351
AD  - Department of Pediatric Infectious Diseases, Al Jalila Children's Hospital, 
      Dubai, United Arab Emirates.
LA  - eng
PT  - Journal Article
DEP - 20211224
PL  - Turkey
TA  - Arch Rheumatol
JT  - Archives of rheumatology
JID - 101639000
PMC - PMC9377180
OTO - NOTNLM
OT  - COVID-19
OT  - Children
OT  - Kawasaki disease
OT  - SARS-CoV-2
OT  - multisystem inflammatory syndrome in children
COIS- Conflict of Interest: The authors declared no conflicts of interest with respect 
      to the authorship and/or publication of this article.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/27 06:01
PMCR- 2021/12/24
CRDT- 2022/08/26 02:28
PHST- 2021/07/02 00:00 [received]
PHST- 2021/07/25 00:00 [accepted]
PHST- 2022/08/26 02:28 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/27 06:01 [medline]
PHST- 2021/12/24 00:00 [pmc-release]
AID - 10.46497/ArchRheumatol.2022.9086 [doi]
PST - epublish
SO  - Arch Rheumatol. 2021 Dec 24;37(2):230-244. doi: 10.46497/ArchRheumatol.2022.9086. 
      eCollection 2022 Jun.